Sai Life Sciences, a leading contract research, development, and manufacturing organization (CRDMO), has inaugurated Unit VI—its first dedicated facility for veterinary active pharmaceutical ingredients (APIs), in Bidar, Karnataka.

Located adjacent to its flagship Unit IV API manufacturing site, the new unit focuses exclusively on veterinary API production, aligning with global demand and industry advancements in animal healthcare. The facility adheres to top-tier standards in safety, sustainability, and regulatory compliance, reinforcing Sai Life Sciences’ commitment to delivering high-quality, scalable manufacturing solutions. 

“This investment strengthens our ability to meet the growing global demand for high-quality veterinary pharmaceuticals while ensuring the highest standards of innovation, efficiency, and sustainability,” said Krishna Kanumuri, CEO & MD, Sai Life Sciences. The move is part of the company’s broader strategy to expand its presence in niche, high-value pharmaceutical segments and support innovator partners with reliable, future-ready solutions for enhancing animal well-being.